Bio intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs. ・This ...

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced ...

COLLECTIVE METALS INC. (CSE: COMT | OTC: CLLMF | FSE: TO1) (the 'Company” or 'Collective”) is pleased to announce that it has amended the terms of its non-brokered private placement financing for ...

KALA BIO, Inc. announces $10.75 million private placement to advance clinical development of KPI-012 for severe eye diseases. KALA Bio, Inc., a clinical-stage biopharmaceutical company focused on ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction ...

Private placement securities continue to offer insurers attractive opportunities to enhance portfolio income, according to a recent Conning report. Conning’s latest Viewpoint commentary, “Private ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Just as with private placements of equity, issuing bonds privately requires careful attention to federal law. Bonds are usually classified as "securities," triggering various regulatory requirements.

Private placement debt offerings offer a compelling alternative to traditional lending for many companies. The legal landscape governing these transactions involves key statutes, regulations, and the ...

The landscape of retirement planning may soon change profoundly. With the recent signing of an executive order aimed at allowing 401(k) plans to include alternative investments such as private equity, ...